Asher Mullard
Impact in
- Oncology top 1%
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Molecular Biology top 1%
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
- RNA Interference and Gene Delivery
Papers in ⓘ
-
- Biotechnology and Related Fields 44
- Co-authors
- Rujun Kang (3 shared papers)Kun Huang (2 shared papers)Anat Yanai (2 shared papers)Pamela Arstikaitis (2 shared papers)Roshni R. Singaraja (2 shared papers)Michael R. Hayden (2 shared papers)Alaa El-Husseini (2 shared papers)Martina Metzler (1 shared paper)
- Journals
- Nature Reviews Drug Discovery (522 papers)Nature (22 papers)The Lancet (14 papers)Nature Reviews Molecular Cell Biology (13 papers)Nature Biotechnology (12 papers)
- Partner nations
- CanadaUnited KingdomUnited States
In The Last Decade
Asher Mullard
568 papers receiving 9.6k citations
Hit Papers
Peers
Comparison fields: 5 of 186
- Oncology 2.1k
- Molecular Biology 4.9k
- Pharmaceutical Science 424
- Immunology 1.3k
- Computational Theory and Mathematics 870
Countries citing papers authored by Asher Mullard
This map shows the geographic impact of Asher Mullard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Asher Mullard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Asher Mullard more than expected).
Fields of papers citing papers by Asher Mullard
This network shows the impact of papers produced by Asher Mullard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Asher Mullard. The network helps show where Asher Mullard may publish in the future.
Co-authors
The 24 scholars most cited alongside Asher Mullard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 604 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | FDA approves 100th monoclonal antibody product Hit paper breakdown → | 2021 | 347 |
| 2 | Targeted protein degraders crowd into the clinic Hit paper breakdown → | 2021 | 276 |
| 3 | 2004 | 258 | |
| 4 | 2006 | 246 | |
| 5 | 2013 | 223 | |
| 6 | 2016 | 222 | |
| 7 | 2012 | 201 | |
| 8 | 2020 | 172 | |
| 9 | 2017 | 152 | |
| 10 | 2019 | 149 | |
| 11 | 2021 | 135 | |
| 12 | 2014 | 134 | |
| 13 | 2012 | 125 | |
| 14 | 2019 | 120 | |
| 15 | 2020 | 115 | |
| 16 | 2016 | 104 | |
| 17 | 2013 | 104 | |
| 18 | 2018 | 103 | |
| 19 | 2021 | 98 | |
| 20 | 2017 | 96 |
About Asher Mullard
Asher Mullard is a scholar working on Molecular Biology, Public Health, Environmental and Occupational Health, Reproductive Medicine, Economics and Econometrics and Oncology, having authored 604 papers that have together received 9.9k indexed citations. Recurring topics across this work include Science, Research, and Medicine (73 papers), Biotechnology and Related Fields (44 papers), Pharmaceutical Economics and Policy (44 papers), Biomedical Ethics and Regulation (43 papers), Health Systems, Economic Evaluations, Quality of Life (35 papers), Monoclonal and Polyclonal Antibodies Research (32 papers), CAR-T cell therapy research (28 papers) and Biosimilars and Bioanalytical Methods (28 papers). The work is most often cited by research in Oncology (2.1k citations), Molecular Biology (4.9k citations), Pharmaceutical Science (424 citations), Immunology (1.3k citations) and Computational Theory and Mathematics (870 citations). Asher Mullard has collaborated with scholars based in Canada, United Kingdom and United States. Frequent co-authors include Rujun Kang, Kun Huang, Anat Yanai, Pamela Arstikaitis, Roshni R. Singaraja, Michael R. Hayden, Alaa El-Husseini, Martina Metzler, Brendan Haigh and Claire‐Anne Gutekunst. Their work appears in journals such as Nature Reviews Drug Discovery, Nature, The Lancet, Nature Reviews Molecular Cell Biology and Nature Biotechnology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.